In the high-stakes world of drug discovery, the ability to visualize the "lock and key" interaction between a therapeutic antibody and its biological target is the difference between a breakthrough and a dead end. For years, cryo-electron microscopy (cryo-EM) has held the crown as the gold standard for atomic-resolution protein structures. However, this crown comes at a heavy price: monumental costs, specialized infrastructure, and, most critically, the notorious bottleneck of sample preparation and grid optimization.
Enter Immuto Scientific, a biotech innovator founded by electrical engineers Faraz A. Choudhury, Ph.D., and Daniel Benjamin, Ph.D. By marrying the precision of mass spectrometry with the predictive power of artificial intelligence, Immuto is effectively bypassing the limitations of traditional structural biology. Their platform is not just a faster alternative; it is a fundamental shift in how scientists map the landscape of protein interactions, particularly in the critical domain of antibody-antigen discovery.
The Structural Biology Bottleneck
The structural biology field has been transformed by the emergence of AI-driven folding tools like AlphaFold, Boltz, Chai, and ByteDance’s Protenix. These models can generate thousands of theoretically plausible protein structures in a fraction of the time it takes to set up a wet-lab experiment. Yet, a significant challenge remains: while these AI models can predict potential structures, they often struggle to rank them accurately. In the complex world of protein folding, the "correct" biological state is frequently buried among thousands of decoys.
"If you were to output, let’s say, 1,000 different possible structures, the correct structure will be in there, but it won’t necessarily be the top-ranked structure," explains Daniel Benjamin, Immuto’s co-founder and CTO.
Traditional cryo-EM offers a way to confirm these structures, but it is an iterative, labor-intensive process. Scientists must optimize grids, manage sample stability, and navigate complex imaging protocols, often turning a week-long project into a months-long ordeal. Immuto Scientific argues that by providing empirical, residue-level constraints through mass spectrometry, they can "ground" these AI predictions, turning a cloud of possibilities into a singular, validated reality.
Chronology of a Biotech Pivot
Immuto Scientific’s trajectory is defined by a commitment to scaling biological data. Founded in 2018, the company was built on the premise that the electrical engineering backgrounds of its founders could be applied to biological workflows to increase throughput.
- 2018: The company is established with a focus on leveraging mass spectrometry as a scalable structural tool.
- Early Development: The team began by benchmarking their platform against standard human cell lines to prove that their methodology could capture protein conformation in environments far more complex than the purified samples required for traditional crystallography.
- Expansion of Scope: Recognizing the need for physiological relevance, Immuto transitioned from simple cell cultures to complex systems, including 3D organoids, tumor tissue resections, and single-cell suspensions.
- 2025 (Last Year): Immuto announced a high-profile partnership with Daiichi Sankyo, focusing on a solid-tumor program that utilizes their technology for novel target discovery and antibody development.
- 2026 (Present): The company is preparing to unveil its v1 antibody-antigen model at the PEGS (Protein Engineering & Cell Therapy Summit) conference, while simultaneously advancing its lead oncology program toward clinical trials in 2027.
Supporting Data: Efficiency at Scale
The most striking metric shared by Immuto is the raw throughput of their platform. According to Benjamin, the current system can process data on approximately 1,000 samples per week. "That roughly translates to something like 100 structures per week," he notes.
This is a step-change in throughput that is virtually impossible with traditional structural biology techniques. The platform achieves this by moving away from the "snapshot" approach of imaging and toward a high-throughput, residue-level analysis.
Why Mass Spectrometry?
The choice of mass spectrometry is deliberate. Unlike cryo-EM, which requires a highly stable, purified, and frozen sample, mass spectrometry can probe proteins in their native environments—including inside living cells. This allows Immuto to observe structural flexibility and disorder, phenomena that are notoriously difficult to resolve with imaging-based techniques.
The company’s approach involves:
- Empirical Constraints: Using mass spec data as an input to narrow down the thousands of AI-predicted structures.
- Native Biology: Utilizing patient-derived models (organoids and tissue resections) to ensure that the structural information is relevant to human disease, rather than an artifact of an immortalized cell line.
- Iterative Engineering: Starting with lower-affinity binders to ensure they hit the correct epitope, then using structural data to guide the affinity maturation process.
Official Perspectives: The Value of "Good Enough"
Immuto does not view itself as the death knell for cryo-EM. Rather, the founders emphasize a complementary relationship. "Cryo-EM is always going to be a relevant tool, especially for proteins that haven’t been solved yet," Benjamin admits. "Cryo-EM gives you a full three-dimensional structure at atomic resolution."
However, for drug discovery teams working under tight deadlines, the "barrier to entry" for cryo-EM is often too high. By contrast, running a mass spectrometer is a standard, repeatable process in modern biopharma. Immuto’s value proposition is that their platform provides enough resolution to make critical drug design decisions—such as epitope mapping—without the agonizing wait time of high-resolution imaging.
"Our technology gives residue-level information, and the results are almost dead-on with what you would see with cryo-EM," says Benjamin. This "near-atomic" level of precision is, in many cases, sufficient to drive a lead candidate into the clinic.
Implications for Drug Discovery
The implications of Immuto’s technology extend far beyond a faster way to look at proteins. By focusing on epitope-first discovery, the company is changing the fundamental logic of antibody engineering.
1. Epitope-Centric Development
Most traditional antibody discovery platforms prioritize binding strength (affinity) above all else. This can lead to candidates that bind strongly but to the wrong part of the protein, or to sites that are irrelevant to the therapeutic mechanism. Immuto, conversely, focuses on the "binding site" first. They identify antibodies that hit the correct biological epitope, even if the initial binding affinity is low. Once the site is locked, they rely on engineering to optimize the strength of the interaction.
2. Clinical Pipeline Potential
Immuto is currently transitioning from a platform-provider model to a pipeline-driven biotech company. Their internal oncology program, set for the clinic in 2027, will be the ultimate test of this methodology. If they can successfully move from "structural insights in a dish" to "durable clinical response in patients," it will validate the idea that structural biology, when paired with high-throughput AI and mass spec, can significantly shorten the drug development cycle.
3. The Future of AI Integration
The partnership with Daiichi Sankyo serves as a litmus test for the industry. Large pharmaceutical companies are increasingly looking for ways to integrate AI not just as a computational tool, but as a workflow component. Immuto’s ability to feed empirical data into AI models acts as a "reality check" for the hallucinations of generative models, potentially setting a new standard for how AI-driven drug discovery pipelines should be constructed.
Conclusion: A New Paradigm
As Immuto Scientific prepares to showcase its v1 antibody-antigen model at the PEGS conference, the industry will be watching closely. The convergence of AI, high-throughput mass spectrometry, and patient-derived biology represents a potent cocktail for drug discovery.
While cryo-EM will continue to dominate the structural biology journals, Immuto is carving out a vital niche in the industrialization of drug discovery. By focusing on speed, scalability, and biological relevance, they are proving that in the quest for the next generation of oncology therapeutics, the most important structure is the one that can be validated quickly enough to save a life. Through their unique blend of electrical engineering discipline and biological insight, Immuto Scientific is not merely observing protein structures—they are engineering a faster route to the clinic.
About the Author
